New EU Guidance To Boost Development Of Vaccines And Treatments For RSV Infections
Executive Summary
Companies wanting more guidance on how to go about developing new vaccines and treatments for respiratory syncytial viral infections will be interested in a new document that has just been put out for consultation by the European Medicines Agency.
You may also be interested in...
Regeneron Phase III Stumble Shows RSV Market Is No Child's Play
Failure of Regeneron's anti-RSV antibody suptavumab (REGN2222) comes at a tough time for the company, as some marketed products disappoint and a long-time alliance with Sanofi comes to an end.
Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine
Sanofi Pasteur and AstraZeneca will collaborate over the UK pharma's monoclonal antibody MEDI8897 to develop and commercialize a pediatric vaccine against respiratory syncytial virus.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.